Philips Titanion MR expands ultra-high-gradient MRI beyond anatomical and functional imaging toward whole-body quantitative biomarkers

May 11, 2026 | 3 minute read

Titanion [1] is designed to enable advanced microstructural and biologically informative imaging, supported by ultra-high gradient performance of 150 mT/m at 250 T/m/s [2]

The system supports biomarker quantification across the full body, helping clinicians generate more precise clinical insights and combining AI-powered software with low power requirements to support broader clinical adoption across a range of care settings

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Titanion MR, its ultra-high-gradient 3.0T MRI, at ISMRM 2026, the leading global forum for magnetic resonance research. Titanion is designed to advance MRI beyond anatomical and functional imaging by enabling clinicians and researchers to apply quantitative and biologically informative imaging approaches. By combining ultra-high gradient performance with AI-enabled workflows, it will support the development and application of imaging biomarkers that reflect tissue microstructure and underlying biological processes across the body.

Titanion MR, a new class of ultra-high-gradient 3.0T MRI

MRI continues to play an increasingly important role in diagnosis and disease monitoring. Philips Titanion MR is designed to advance this role by enabling imaging biomarkers that reflect tissue microstructure and function, supporting more precise and quantitative clinical insights across a range of applications, including neurology and oncology.

By combining ultra-high gradient performance with advanced AI-powered software, we are helping clinicians and researchers gain deeper insight into tissue microstructure and underlying biology, supporting the next phase of MRI toward more precise and quantitative results, enabling increasingly proactive and personalized clinical insights.

- Ioannis Panagiotelis, Business Leader Magnetic Resonance at Philips

“Titanion MR represents a significant step forward for 3.0T MRI at Philips, expanding our ability to quantify imaging biomarkers across the body, especially in the brain, and bring advanced imaging capabilities into routine clinical practice,” said Ioannis Panagiotelis, Business Leader Magnetic Resonance at Philips. “By combining ultra-high gradient performance with advanced AI-powered software, we are helping clinicians and researchers gain deeper insight into tissue microstructure and underlying biology, supporting the next phase of MRI toward more precise and quantitative results, enabling increasingly proactive and personalized clinical insights.”

Built for breakthroughs in imaging biomarkers

Titanion is designed to bring ultra-high gradient performance to Philips’ 3.0T MRI portfolio, including:

Actual gradient strength of 150 mT/m gradient at slew rate of 250 T/m/s [2], enhancing visibility of microstructural tissue, advancing detailed research in neurodegenerative diseases
High G_rms performance, sustaining strong gradients over time to support advanced diffusion and microstructural imaging
Low eddy current design, providing exceptional signal fidelity and reducing image distortion for more reliable quantitative measurements
Large 55 cm field of view (FOV), enabling comprehensive anatomical coverage in a single exam, from brain to extremities, supporting true whole-body imaging

Together, these capabilities will enable advanced quantitative and microstructural imaging, supporting the development and broader clinical application of imaging biomarkers and their translation into more precise, data-driven clinical care and research.

Intelligent performance for clinical practice

Titanion provides upgrades to Philips’ hardware innovation, combined with the company’s latest software advancements. With SmartSpeed Precise, users can achieve up to 80% sharper images [3] and up to 3x faster scan times [4], supporting productivity and diagnostic confidence.

Titanion is designed with operational efficiency in mind, with power requirements of only 115 kVA [X], supporting installation in a wider range of clinical environments without extensive infrastructure upgrades, helping bring high-performance MRI capabilities to more sites.

Availability and configuration options for Titanion will depend on existing MR configurations and customer environments.

This webpage is intended for non-US audiences only. Titanion is a Work in Progress and not available in any jurisdiction. Its future availability cannot be guaranteed.

Sources

[1] Titanion is considered Work in Progress and is not FDA cleared or CE marked and not available for sale.
[2] Pending verification
[3] Compared to conventional (SENSE / Compressed SENSE / SmartSpeed AI) imaging. Sharpness was evaluated with phantom scanning.
[4] Compared to Philips SENSE imaging.

About Royal Philips

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.